JP Morgan 2024 – Graham Heap
Just over a year ago, Takeda acquired a promising immunotherapy candidate, TAK-279, from Boston-based Nimbus Therapeutics.
At the Nikko Hotel on the sidelines of JP Morgan, Takeda VP and TAK-279 franchise lead Graham Heap sat down with editor-in-chief Jonah Comstock to discuss the highly selective allosteric TYK-2 inhibitor.
Heap discusses the progress they’ve made moving that asset forwards across a number of different indications, including psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), and inflammatory bowel disease. He shares some thoughts about their development strategy, the advantages of the candidate, and an update on the various trials.
Stay tuned also for a discussion of broader trends in immunotherapy and even some thoughts about Takeda’s M&A mindset and goals in 2024.
Check out the video below for the full interview.
